Posts Tagged ‘Brenden-Colson Center for Pancreatic Care’

New funding for a dire need: Pancreas cancer early detection

With a $250,000 award from the Pancreatic Cancer Action Network, researchers will seek to validate biomarkers able to detect pancreas cancer months or years before patients experience overt symptoms of the disease.   Pancreatic ductal adenocarcinoma is the deadliest of the major cancer types, with a five-year survival rate of less than 10 percent. Unlike the other major causes of cancer mortality, pancreatic cancer is increasing in both incidence and number of deaths each year. Principal investigator Brett Sheppard, … Read More

Marquam Hill Lecture: Confronting the unexpected rise of pancreas cancer

Unlike the other major causes of cancer mortality, pancreatic cancer is increasing in both incidence and number of deaths each year. Despite improvements in early detection and therapy that have greatly improved outcomes in other cancers, the five-year survival rate remains less than 8 percent for people diagnosed with pancreatic cancer. It’s on a course to become the second largest cause of cancer death within five to ten years – ahead of colorectal, breast, prostate … Read More

Advancing a potential blood test for pancreatic cancer

Immunovia’s “IMMray” technology uses an antibody microarray to detect the protein signature of pancreatic cancer in blood samples.   The Swedish biotech firm Immunovia reached another milestone with the OHSU Knight Cancer Institute in developing a blood test to speed the diagnosis of pancreatic cancer. Immunovia’s antibody microarray correctly classified 96 percent of patients with stage I or II pancreatic ductal adenocarcinoma in a retrospective study using samples from North American pancreatic cancer patients. These results match … Read More

Targeting leukemia with drug combinations

Targeting leukemia with drug combinations

Cancer researchers have devised a way to rapidly screen combinations of drugs to identify pairs of agents most likely to work synergistically against some of the most difficult to treat forms of leukemia.